董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 何为无 | 男 | Chairman of the board and CEO | 59 | 966.54万美元 | 295.79 | 2024-03-28 |
| Thomas Folinsbee | 男 | Independent Director | 56 | 未披露 | 未持股 | 2024-03-28 |
| 苏震波 | 男 | Independent Director | 48 | 未披露 | 未持股 | 2024-03-28 |
| 曾学波 | 男 | Independent Director | 38 | 未披露 | 未持股 | 2024-03-28 |
| 吴越 | 男 | Independent Director | 60 | 15.05万美元 | 未持股 | 2024-03-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 何为无 | 男 | Chairman of the board and CEO | 59 | 966.54万美元 | 295.79 | 2024-03-28 |
| 张炜 | 男 | President and Principal Financial Officer | 65 | 255.52万美元 | 19.87 | 2024-03-28 |
| Alexander A. Zukiwski | 男 | Global Chief Medical Officer | 66 | 118.14万美元 | 未持股 | 2024-03-28 |
| 王春华 | 女 | Chief Operation Officer | 52 | 未披露 | 未持股 | 2024-03-28 |
| 钱坤 | 女 | Global Controller | 42 | 未披露 | 未持股 | 2024-03-28 |
| 高玮 | 女 | General Counsel | 42 | 未披露 | 未持股 | 2024-03-28 |
| Huang Hai | 男 | Global Chief Commercial Officer | 55 | 未披露 | 未持股 | 2024-03-28 |
董事简历
中英对照 | 中文 | 英文- 何为无
-
何为无，2012年2月到2013年5月，他是公司的执行主席，此后继续担任董事长。自1995年以来，他曾任OriGene技术公司的首席执行官和董事长。他也是新兴技术合作伙伴的创始人和普通合伙人，一家成立于2000年的生命科学专注于风险基金公司。从1993年到1996年，他是在人类基因组科学的资深科学家。在此之前他是一个马萨诸塞州总医院和梅奥诊所的研究员。他从贝勒医学院获得了他的博士学位，从宾夕法尼亚大学沃顿商学院获得了MBA学位。
Wei Wu He,has served as chairman of the board of directors and CEO of CASI since April 2, 2019. Dr. He served as executive chairman of CASI Delaware from February 23, 2018 to April 2, 2019, as chairman to the board of directors of CASI Delaware from May 2013 to February 23, 2018, and as executive chairman from February 2012 to May 2013. Dr. He has been serving as executive chairman of Human Longevity Inc. (a privately-held biotechnology firm specializing in combining DNA sequencing with machine learning) since July 2019. He also is the founder and general partner of Emerging Technology Partners, LLC, a life sciences focused venture fund established in 2000. Dr. He has been involved in founding or funding over 20 biotech companies throughout his career, some of which went on to be acquired by significantly larger firms. In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 25 research publications and inventor of over 30 issued patents. Dr. He received his Ph.D. from Baylor College of Medicine and MBA from The Wharton School of University of Pennsylvania. - 何为无，2012年2月到2013年5月，他是公司的执行主席，此后继续担任董事长。自1995年以来，他曾任OriGene技术公司的首席执行官和董事长。他也是新兴技术合作伙伴的创始人和普通合伙人，一家成立于2000年的生命科学专注于风险基金公司。从1993年到1996年，他是在人类基因组科学的资深科学家。在此之前他是一个马萨诸塞州总医院和梅奥诊所的研究员。他从贝勒医学院获得了他的博士学位，从宾夕法尼亚大学沃顿商学院获得了MBA学位。
- Wei Wu He,has served as chairman of the board of directors and CEO of CASI since April 2, 2019. Dr. He served as executive chairman of CASI Delaware from February 23, 2018 to April 2, 2019, as chairman to the board of directors of CASI Delaware from May 2013 to February 23, 2018, and as executive chairman from February 2012 to May 2013. Dr. He has been serving as executive chairman of Human Longevity Inc. (a privately-held biotechnology firm specializing in combining DNA sequencing with machine learning) since July 2019. He also is the founder and general partner of Emerging Technology Partners, LLC, a life sciences focused venture fund established in 2000. Dr. He has been involved in founding or funding over 20 biotech companies throughout his career, some of which went on to be acquired by significantly larger firms. In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 25 research publications and inventor of over 30 issued patents. Dr. He received his Ph.D. from Baylor College of Medicine and MBA from The Wharton School of University of Pennsylvania.
- Thomas Folinsbee
-
Thomas Folinsbee，是Summit Healthcare Acquisition Corp.的独立董事，拥有超过25年的金融和证券专业经验。自2019年以来，Folinsbee先生一直担任Shanghai Alebund Pharmaceuticals Ltd.（中国制药公司）的业务发展顾问，负责药品inlicensing和outlicensing交易。Folinsbee是徐诺药业有限公司的独立董事之一。 Folinsbee先生是3SBio Inc.战略投资部门的企业发展总监，专注于在加拿大，澳大利亚和日本市场并寻找业务发展机会，包括许可，分销和并购。 Folinsbee先生于2009年加入3SBio，一家生物技术公司，负责管理3SBio的投资者关系活动，并且是管理集团的成员，该集团于2013年5月从纳斯达克退市3SBio，并于2016年6月在香港证券交易所重新上市。此外，自2011年以来，Folinsbee先生一直与日本公司Hisanaga Seisakusho Co. Ltd的董事会合作，在那里他帮助推出了Hisanaga在印度的销售平台，并设计了商业智能系统以支持企业转型。 2001年，Folinsbee先生成立了Optivest Systems Ltd，并开发了专有的研究数据库，以支持机构投资策略。 2006年，Folinsbee先生加入法国巴黎银行的亚洲执行服务台，帮助机构投资者实施统计套利策略和交易后分析。 2008年，他重新加入麦格理证券香港有限公司（Macquarie Equities Hong Kong Limited）的替代策略部门，与股票研究平台合作，打造多空交易策略。 Folinsbee先生曾于1998年至2001年期间在麦格理大学工作。Folinsbee先生于1990年毕业于麦吉尔大学，获得商业学士学位，主修金融和国际业务。
Thomas Folinsbee,has over 25 years of experience as a financial and securities professional. He is the founder of Optivest Canada Ltd, a management consulting company focused on business development and investment research mandates for clients in the healthcare industry. Mr. Folinsbee was previously the director of corporate development for 3Sbio Inc. from 2009 to 2019. From 2017 to 2019, Mr. Folinsbee also served as independent director of Bison Capital Acquisition Corporation and was a member of the audit and compensation committees after the merger with Xynomic Pharmaceuticals. From 2011 to 2016, he also worked for Hisanaga Seisakusho Co. Ltd., a Japanese manufacturing company. Before joining 3Sbio Inc., he also worked at Macquarie Equities, BNP Paribas and Optivest Systems Ltd. Mr. Folinsbee graduated in 1990 from McGill University with a bachelor of commerce degree concentrating in finance and international business and is CFA charter holder. - Thomas Folinsbee，是Summit Healthcare Acquisition Corp.的独立董事，拥有超过25年的金融和证券专业经验。自2019年以来，Folinsbee先生一直担任Shanghai Alebund Pharmaceuticals Ltd.（中国制药公司）的业务发展顾问，负责药品inlicensing和outlicensing交易。Folinsbee是徐诺药业有限公司的独立董事之一。 Folinsbee先生是3SBio Inc.战略投资部门的企业发展总监，专注于在加拿大，澳大利亚和日本市场并寻找业务发展机会，包括许可，分销和并购。 Folinsbee先生于2009年加入3SBio，一家生物技术公司，负责管理3SBio的投资者关系活动，并且是管理集团的成员，该集团于2013年5月从纳斯达克退市3SBio，并于2016年6月在香港证券交易所重新上市。此外，自2011年以来，Folinsbee先生一直与日本公司Hisanaga Seisakusho Co. Ltd的董事会合作，在那里他帮助推出了Hisanaga在印度的销售平台，并设计了商业智能系统以支持企业转型。 2001年，Folinsbee先生成立了Optivest Systems Ltd，并开发了专有的研究数据库，以支持机构投资策略。 2006年，Folinsbee先生加入法国巴黎银行的亚洲执行服务台，帮助机构投资者实施统计套利策略和交易后分析。 2008年，他重新加入麦格理证券香港有限公司（Macquarie Equities Hong Kong Limited）的替代策略部门，与股票研究平台合作，打造多空交易策略。 Folinsbee先生曾于1998年至2001年期间在麦格理大学工作。Folinsbee先生于1990年毕业于麦吉尔大学，获得商业学士学位，主修金融和国际业务。
- Thomas Folinsbee,has over 25 years of experience as a financial and securities professional. He is the founder of Optivest Canada Ltd, a management consulting company focused on business development and investment research mandates for clients in the healthcare industry. Mr. Folinsbee was previously the director of corporate development for 3Sbio Inc. from 2009 to 2019. From 2017 to 2019, Mr. Folinsbee also served as independent director of Bison Capital Acquisition Corporation and was a member of the audit and compensation committees after the merger with Xynomic Pharmaceuticals. From 2011 to 2016, he also worked for Hisanaga Seisakusho Co. Ltd., a Japanese manufacturing company. Before joining 3Sbio Inc., he also worked at Macquarie Equities, BNP Paribas and Optivest Systems Ltd. Mr. Folinsbee graduated in 1990 from McGill University with a bachelor of commerce degree concentrating in finance and international business and is CFA charter holder.
- 苏震波
-
苏震波，在生物科学行业拥有丰富的经验，他是生命科学行业的知名投资人。苏先生目前是Guangzhou Redhill Capital Investment Management Co., Ltd的合伙人，这是一家总部位于广州的领先的生命科学风险投资公司，他于2018年与他人共同创立了Guangzhou Redhill Capital Investment Management Co., Ltd.在加入Redhill之前，他自2013年起担任深圳共享投资医疗基金的管理合伙人。苏先生曾担任生物科学行业多家公司的执行董事，如TCRCure、Genetron、Medprint、尤文图斯、Hocermed、Polyrey、Pandamed、Light Vision和Meyer FSMP。在Su先生开始投资生涯之前，他曾在2007年至2012年期间担任Novartis 旗下公司Alcon中国的董事。在苏先生职业生涯的早期，他曾在Johnson & Johnson的医疗分公司工作。苏先生拥有广东医学院医学学士学位、中山大学公共医疗保健政策和医学法学硕士学位以及芝加哥大学工商管理硕士学位。
Zhenbo Su,has extensive experiences in the bioscience industry, and he has been a well-known investor in the life-science industry. Mr. Su is currently a partner of Guangzhou Redhill Capital Investment Management Co., Ltd, a leading life-science focused venture capital firm based in Guangzhou, which he co-founded in 2018. Prior to Mr. Su's efforts in Redhill, he has served as the managing partner of Shenzhen Shared Investment Medical Fund since 2013. Mr. Su has served as an executive director of multiple companies in bioscience industry, such as TCRCure, Genetron, Medprint, Juventus, Hocermed, Polyrey, Pandamed, Light Vision and Meyer FSMP. Before Mr. Su started his career in investment, he was a director at Alcon China, a Novartis company, from 2007 to 2012. Earlier in Mr. Su's career, he once worked at Johnson & Johnson in medical branch. Mr. Su holds a bachelor's degree in medicine from Guangdong College of Medicine, a master's degree in public healthcare policy and medical law from Sun Yat-sen University, and MBA from the University of Chicago. - 苏震波，在生物科学行业拥有丰富的经验，他是生命科学行业的知名投资人。苏先生目前是Guangzhou Redhill Capital Investment Management Co., Ltd的合伙人，这是一家总部位于广州的领先的生命科学风险投资公司，他于2018年与他人共同创立了Guangzhou Redhill Capital Investment Management Co., Ltd.在加入Redhill之前，他自2013年起担任深圳共享投资医疗基金的管理合伙人。苏先生曾担任生物科学行业多家公司的执行董事，如TCRCure、Genetron、Medprint、尤文图斯、Hocermed、Polyrey、Pandamed、Light Vision和Meyer FSMP。在Su先生开始投资生涯之前，他曾在2007年至2012年期间担任Novartis 旗下公司Alcon中国的董事。在苏先生职业生涯的早期，他曾在Johnson & Johnson的医疗分公司工作。苏先生拥有广东医学院医学学士学位、中山大学公共医疗保健政策和医学法学硕士学位以及芝加哥大学工商管理硕士学位。
- Zhenbo Su,has extensive experiences in the bioscience industry, and he has been a well-known investor in the life-science industry. Mr. Su is currently a partner of Guangzhou Redhill Capital Investment Management Co., Ltd, a leading life-science focused venture capital firm based in Guangzhou, which he co-founded in 2018. Prior to Mr. Su's efforts in Redhill, he has served as the managing partner of Shenzhen Shared Investment Medical Fund since 2013. Mr. Su has served as an executive director of multiple companies in bioscience industry, such as TCRCure, Genetron, Medprint, Juventus, Hocermed, Polyrey, Pandamed, Light Vision and Meyer FSMP. Before Mr. Su started his career in investment, he was a director at Alcon China, a Novartis company, from 2007 to 2012. Earlier in Mr. Su's career, he once worked at Johnson & Johnson in medical branch. Mr. Su holds a bachelor's degree in medicine from Guangdong College of Medicine, a master's degree in public healthcare policy and medical law from Sun Yat-sen University, and MBA from the University of Chicago.
- 曾学波
-
曾学波，自2016年起担任IDG资本的执行董事，专注于药物开发、生物科技、诊断设备和医疗服务领域的投资。曾先生于2008年在桂林医药的质量控制部门开始了他的职业生涯，并很快成为了一名专门从事生命科学投资的投资经理。在加入IDG资本之前，他曾于2010年至2016年在中国另外两家著名的私募股权公司担任投资经理。曾先生是多家民营和上市公司的董事会成员，包括上海模式生物和科伦生物。曾先生在中国青海民族大学获得药学学士学位。
Xuebo Zeng,has been an executive director at IDG Capital since 2016, focusing on the investment in drug development, biotechnology, diagnostic devices and medical services. Mr. Zeng started his career in quality control department of Guilin Pharma in 2008 and soon became an investment manager specialized in life sciences investments. Prior to joining IDG Capital, he worked as an investment manager in two other famous private equity firms in China from 2010 to 2016. Mr. Zeng is a member of the board of directors of a number of private and listed companies, including Shanghai Model Organisms and Kelun-Biotech. Mr. Zeng received a bachelor's degree in pharmacy from Qinghai Nationalities University, China. - 曾学波，自2016年起担任IDG资本的执行董事，专注于药物开发、生物科技、诊断设备和医疗服务领域的投资。曾先生于2008年在桂林医药的质量控制部门开始了他的职业生涯，并很快成为了一名专门从事生命科学投资的投资经理。在加入IDG资本之前，他曾于2010年至2016年在中国另外两家著名的私募股权公司担任投资经理。曾先生是多家民营和上市公司的董事会成员，包括上海模式生物和科伦生物。曾先生在中国青海民族大学获得药学学士学位。
- Xuebo Zeng,has been an executive director at IDG Capital since 2016, focusing on the investment in drug development, biotechnology, diagnostic devices and medical services. Mr. Zeng started his career in quality control department of Guilin Pharma in 2008 and soon became an investment manager specialized in life sciences investments. Prior to joining IDG Capital, he worked as an investment manager in two other famous private equity firms in China from 2010 to 2016. Mr. Zeng is a member of the board of directors of a number of private and listed companies, including Shanghai Model Organisms and Kelun-Biotech. Mr. Zeng received a bachelor's degree in pharmacy from Qinghai Nationalities University, China.
- 吴越
-
吴越，自2013年4月他一直是公司的董事。他是Crown Bioscience公司的首席执行官，一家在肿瘤领域拥有超过300名员工的药物发现和临床前研究机构。在2006年，他联合创立了该公司。Crown Bioscience公司之前，从2004年到2006年，亚历克斯是Starvax International公司的首席商务官，一家专注于开发新型治疗药物治疗传染性疾病和癌症的生物制药研发公司。Starvax之前，从2001年到2004年，他事Burrill公司亚洲业务负责人，一家生命科学的风险资本和商业银行。他还共同创立了Unimicro Technologies公司，并担任首席运营官，一个生命科学仪器公司。他在Hoffmann-La公司开始他的职业生涯，他是业务发展和战略规划的经理。他获得了中国复旦大学生物化学学士学位 ，伊利诺斯州大学的生物化学硕士，和加州大学伯克利分校分子细胞生物学博士学位和MBA学位。
Y. Alexander Wu,has been a director of CASI since April 2013. From 2006 to 2017, Dr. Wu was co-founder and chief executive officer of Crown Bioscience, Inc., a drug discovery and preclinical research organization in the oncology sector with over 600 employees, which was acquired by JSR for over US$400 million in 2017. Before co-founding Crown Bioscience, Dr. Wu was chief business officer of Starvax International Inc., a biopharmaceutical R&D company focusing on the development of novel therapeutic drugs for the treatment of infectious disease and cancer. Prior to Starvax, he was the head of Asian Operations with Burrill & Company, a life science venture capital and merchant bank. Dr. Wu also co-founded and was chief operating officer of Unimicro Technologies, a life science instrumentation company. He started his career with Hoffmann-La Roche, where he was manager of business development and strategic planning. Dr. Wu obtained his B.S. in biochemistry from Fudan University, China, a M.S. in biochemistry from the University of Illinois, and a Ph.D. in molecular cell biology and MBA from the University of California, Berkeley. - 吴越，自2013年4月他一直是公司的董事。他是Crown Bioscience公司的首席执行官，一家在肿瘤领域拥有超过300名员工的药物发现和临床前研究机构。在2006年，他联合创立了该公司。Crown Bioscience公司之前，从2004年到2006年，亚历克斯是Starvax International公司的首席商务官，一家专注于开发新型治疗药物治疗传染性疾病和癌症的生物制药研发公司。Starvax之前，从2001年到2004年，他事Burrill公司亚洲业务负责人，一家生命科学的风险资本和商业银行。他还共同创立了Unimicro Technologies公司，并担任首席运营官，一个生命科学仪器公司。他在Hoffmann-La公司开始他的职业生涯，他是业务发展和战略规划的经理。他获得了中国复旦大学生物化学学士学位 ，伊利诺斯州大学的生物化学硕士，和加州大学伯克利分校分子细胞生物学博士学位和MBA学位。
- Y. Alexander Wu,has been a director of CASI since April 2013. From 2006 to 2017, Dr. Wu was co-founder and chief executive officer of Crown Bioscience, Inc., a drug discovery and preclinical research organization in the oncology sector with over 600 employees, which was acquired by JSR for over US$400 million in 2017. Before co-founding Crown Bioscience, Dr. Wu was chief business officer of Starvax International Inc., a biopharmaceutical R&D company focusing on the development of novel therapeutic drugs for the treatment of infectious disease and cancer. Prior to Starvax, he was the head of Asian Operations with Burrill & Company, a life science venture capital and merchant bank. Dr. Wu also co-founded and was chief operating officer of Unimicro Technologies, a life science instrumentation company. He started his career with Hoffmann-La Roche, where he was manager of business development and strategic planning. Dr. Wu obtained his B.S. in biochemistry from Fudan University, China, a M.S. in biochemistry from the University of Illinois, and a Ph.D. in molecular cell biology and MBA from the University of California, Berkeley.
高管简历
中英对照 | 中文 | 英文- 何为无
何为无，2012年2月到2013年5月，他是公司的执行主席，此后继续担任董事长。自1995年以来，他曾任OriGene技术公司的首席执行官和董事长。他也是新兴技术合作伙伴的创始人和普通合伙人，一家成立于2000年的生命科学专注于风险基金公司。从1993年到1996年，他是在人类基因组科学的资深科学家。在此之前他是一个马萨诸塞州总医院和梅奥诊所的研究员。他从贝勒医学院获得了他的博士学位，从宾夕法尼亚大学沃顿商学院获得了MBA学位。
Wei Wu He,has served as chairman of the board of directors and CEO of CASI since April 2, 2019. Dr. He served as executive chairman of CASI Delaware from February 23, 2018 to April 2, 2019, as chairman to the board of directors of CASI Delaware from May 2013 to February 23, 2018, and as executive chairman from February 2012 to May 2013. Dr. He has been serving as executive chairman of Human Longevity Inc. (a privately-held biotechnology firm specializing in combining DNA sequencing with machine learning) since July 2019. He also is the founder and general partner of Emerging Technology Partners, LLC, a life sciences focused venture fund established in 2000. Dr. He has been involved in founding or funding over 20 biotech companies throughout his career, some of which went on to be acquired by significantly larger firms. In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 25 research publications and inventor of over 30 issued patents. Dr. He received his Ph.D. from Baylor College of Medicine and MBA from The Wharton School of University of Pennsylvania.- 何为无，2012年2月到2013年5月，他是公司的执行主席，此后继续担任董事长。自1995年以来，他曾任OriGene技术公司的首席执行官和董事长。他也是新兴技术合作伙伴的创始人和普通合伙人，一家成立于2000年的生命科学专注于风险基金公司。从1993年到1996年，他是在人类基因组科学的资深科学家。在此之前他是一个马萨诸塞州总医院和梅奥诊所的研究员。他从贝勒医学院获得了他的博士学位，从宾夕法尼亚大学沃顿商学院获得了MBA学位。
- Wei Wu He,has served as chairman of the board of directors and CEO of CASI since April 2, 2019. Dr. He served as executive chairman of CASI Delaware from February 23, 2018 to April 2, 2019, as chairman to the board of directors of CASI Delaware from May 2013 to February 23, 2018, and as executive chairman from February 2012 to May 2013. Dr. He has been serving as executive chairman of Human Longevity Inc. (a privately-held biotechnology firm specializing in combining DNA sequencing with machine learning) since July 2019. He also is the founder and general partner of Emerging Technology Partners, LLC, a life sciences focused venture fund established in 2000. Dr. He has been involved in founding or funding over 20 biotech companies throughout his career, some of which went on to be acquired by significantly larger firms. In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 25 research publications and inventor of over 30 issued patents. Dr. He received his Ph.D. from Baylor College of Medicine and MBA from The Wharton School of University of Pennsylvania.
- 张炜
张炜于2018年9月加入Casi Pharmaceuticals, Inc.，担任CASI Beijing Pharmaceuticals Co., Ltd.（现称CASI Pharmaceuticals （China） Co., Ltd.（简称CASI China））的总裁，CASI Pharmaceuticals （China） Co., Ltd.是Casi Pharmaceuticals, Inc.的子公司，2019年9月，他升任总裁，在美国医疗保健和生物制药行业拥有20多年的管理经验。亚太地区和中国。在加入北京办事处之前，张炜是Novartis Group（中国）的副总裁、公共事务和企业责任负责人，专注于公共事务/公共关系战略，包括启动Novartis Group （China）政策，重点关注国家医疗产品管理局（NMPA）的新药审批改革、知识产权保护，通用质量一致性评估和生物仿制药新法规。2021-2016年，张炜担任Sandoz Pharmaceutical（China）首席执行官。张炜还曾在美国和亚太地区的Bayer医疗和Baxter International Corporation担任高管领导职务。张炜拥有中国科学技术大学核物理学士和硕士学位，加州大学洛杉矶分校（UCLA）市场营销/金融MBA学位，并在犹他大学接受政治学博士培训。
Wei Zhang,joined CASI in September 2018 as president of CASI (Beijing) Pharmaceuticals Co., Ltd., now known as CASI Pharmaceuticals (China) Co., Ltd. ("CASI China"), which is a subsidiary of CASI, and his role expanded to president and principal financial officer of CASI in September 2019. Mr. Zhang has more than 20 years management experience in the healthcare and biopharmaceutical industries in the U.S., Asia Pacific, and China. Prior to joining CASI's Beijing office, Mr. Zhang was vice president, head of public affairs and corporate responsibility at Novartis Group (China) focusing on the public affairs/public relations strategy including initiating Novartis' China policy focusing on NMPA new drug approval reform, IP protection, generic quality consistency evaluation and new regulations on biosimilars. From 2011 to 2016, he was chief executive officer of Sandoz Pharmaceutical (China), a Novartis Company. Mr. Zhang has also held executive leadership roles with Bayer Healthcare and Baxter International Corporation in the U.S. and Asia Pacific. He holds a bachelor and master degree in nuclear physics from University of Science & Technology of China, an MBA in marketing/finance from the University of California at Los Angeles (UCLA), and received Ph.D. training in political science from University of Utah.- 张炜于2018年9月加入Casi Pharmaceuticals, Inc.，担任CASI Beijing Pharmaceuticals Co., Ltd.（现称CASI Pharmaceuticals （China） Co., Ltd.（简称CASI China））的总裁，CASI Pharmaceuticals （China） Co., Ltd.是Casi Pharmaceuticals, Inc.的子公司，2019年9月，他升任总裁，在美国医疗保健和生物制药行业拥有20多年的管理经验。亚太地区和中国。在加入北京办事处之前，张炜是Novartis Group（中国）的副总裁、公共事务和企业责任负责人，专注于公共事务/公共关系战略，包括启动Novartis Group （China）政策，重点关注国家医疗产品管理局（NMPA）的新药审批改革、知识产权保护，通用质量一致性评估和生物仿制药新法规。2021-2016年，张炜担任Sandoz Pharmaceutical（China）首席执行官。张炜还曾在美国和亚太地区的Bayer医疗和Baxter International Corporation担任高管领导职务。张炜拥有中国科学技术大学核物理学士和硕士学位，加州大学洛杉矶分校（UCLA）市场营销/金融MBA学位，并在犹他大学接受政治学博士培训。
- Wei Zhang,joined CASI in September 2018 as president of CASI (Beijing) Pharmaceuticals Co., Ltd., now known as CASI Pharmaceuticals (China) Co., Ltd. ("CASI China"), which is a subsidiary of CASI, and his role expanded to president and principal financial officer of CASI in September 2019. Mr. Zhang has more than 20 years management experience in the healthcare and biopharmaceutical industries in the U.S., Asia Pacific, and China. Prior to joining CASI's Beijing office, Mr. Zhang was vice president, head of public affairs and corporate responsibility at Novartis Group (China) focusing on the public affairs/public relations strategy including initiating Novartis' China policy focusing on NMPA new drug approval reform, IP protection, generic quality consistency evaluation and new regulations on biosimilars. From 2011 to 2016, he was chief executive officer of Sandoz Pharmaceutical (China), a Novartis Company. Mr. Zhang has also held executive leadership roles with Bayer Healthcare and Baxter International Corporation in the U.S. and Asia Pacific. He holds a bachelor and master degree in nuclear physics from University of Science & Technology of China, an MBA in marketing/finance from the University of California at Los Angeles (UCLA), and received Ph.D. training in political science from University of Utah.
- Alexander A. Zukiwski
Alexander A. Zukiwski于2017年4月加入公司，担任首席医疗官。在加入公司之前，Alexander A.Zukiwski是Arno Therapeutics的首席执行官和首席医疗官，自2014年起担任Arno Theapeutics“Arno”的董事。在2007年加入Arno之前，Alexander A.Zukiwski担任MedImmune LLC（“MedImmunce”）的首席医疗官和临床研究执行副总裁。在加入MedImmune之前，Alexander A.Zukiwski在强生公司（“强生”）的医疗事务和强生制药研发有限责任公司（“J&JPRD”）的临床开发职能部门担任多个职位，职责日益增加；Centocor研发和Ortho Biotech。在加入强生之前，Alexander A.Zukiwski曾在Hoffmann LaRoche、Glaxo Wellcome和Rhone Poulenc Rorer等制药公司担任临床肿瘤学职位。Alexander A.Zukiwski在全球药物开发方面拥有超过21年的经验，并支持许多成功的肿瘤治疗剂的临床评估和注册，包括Taxotere、Xeloda、Procrit/Eprex、Velcade、Yondelis和Doxil。Alexander A.Zukiwski曾担任Gem Pharmaceuticals，LLC医疗顾问委员会成员，并担任Ambit Biosciences Corporation董事。Alexander A.Zukiwski拥有阿尔伯塔大学药学学士学位和卡尔加里大学医学博士学位。亚历山大·祖基夫斯基（Alexander A.Zukowski）在俄亥俄州阿克伦的圣托马斯医院医疗中心（St.Thomas Hospital Medical Center）和德克萨斯大学医学博士安德森癌症中心（University of Texas MD Anderson Cancer Center）进行了研究生培训。
Alexander A. Zukiwski,joined CASI in April of 2017 as chief medical officer, and he currently serves as executive vice president and chief medical officer. Prior to joining the Company, Dr. Zukiwski was chief executive officer and chief medical officer of Arno Therapeutics and has been a director of Arno Therapeutics ("Arno") since 2014. At Arno, his responsibilities included leading the clinical development and regulatory affairs teams to support the company's pipeline. Prior to joining Arno in 2007, Dr. Zukiwski served as chief medical officer and executive vice president of clinical research at MedImmune LLC ("MedImmune"). Prior to MedImmune, Dr. Zukiwski held several roles of increasing responsibility at Johnson & Johnson's ("J&J") medical affairs and clinical development functions at Johnson & Johnson Pharmaceutical Research & Development LLC ("J&JPRD"), Centocor R&D and Ortho Biotech. Before joining J&J, he served in clinical oncology positions at pharmaceutical companies such as Hoffmann-LaRoche, Glaxo Wellcome and Rhone-Poulenc Rorer. Dr. Zukiwski has more than 21 years of experience in global drug development and supported the clinical evaluation and registration of many successful oncology therapeutic agents, including Taxotere, Xeloda, Procrit/Eprex, Velcade, Yondelis, and Doxil. He previously served as a member of medical advisory board at Gem Pharmaceuticals, LLC and served as a director of Ambit Biosciences Corporation. Dr. Zukiwski holds a bachelor's degree in pharmacy from the Universityof Alberta and a Doctor of Medicine degree from the University of Calgary. He conducted his post-graduate training at St. Thomas Hospital Medical Center in Akron, Ohio and the University of Texas MD Anderson Cancer Center.- Alexander A. Zukiwski于2017年4月加入公司，担任首席医疗官。在加入公司之前，Alexander A.Zukiwski是Arno Therapeutics的首席执行官和首席医疗官，自2014年起担任Arno Theapeutics“Arno”的董事。在2007年加入Arno之前，Alexander A.Zukiwski担任MedImmune LLC（“MedImmunce”）的首席医疗官和临床研究执行副总裁。在加入MedImmune之前，Alexander A.Zukiwski在强生公司（“强生”）的医疗事务和强生制药研发有限责任公司（“J&JPRD”）的临床开发职能部门担任多个职位，职责日益增加；Centocor研发和Ortho Biotech。在加入强生之前，Alexander A.Zukiwski曾在Hoffmann LaRoche、Glaxo Wellcome和Rhone Poulenc Rorer等制药公司担任临床肿瘤学职位。Alexander A.Zukiwski在全球药物开发方面拥有超过21年的经验，并支持许多成功的肿瘤治疗剂的临床评估和注册，包括Taxotere、Xeloda、Procrit/Eprex、Velcade、Yondelis和Doxil。Alexander A.Zukiwski曾担任Gem Pharmaceuticals，LLC医疗顾问委员会成员，并担任Ambit Biosciences Corporation董事。Alexander A.Zukiwski拥有阿尔伯塔大学药学学士学位和卡尔加里大学医学博士学位。亚历山大·祖基夫斯基（Alexander A.Zukowski）在俄亥俄州阿克伦的圣托马斯医院医疗中心（St.Thomas Hospital Medical Center）和德克萨斯大学医学博士安德森癌症中心（University of Texas MD Anderson Cancer Center）进行了研究生培训。
- Alexander A. Zukiwski,joined CASI in April of 2017 as chief medical officer, and he currently serves as executive vice president and chief medical officer. Prior to joining the Company, Dr. Zukiwski was chief executive officer and chief medical officer of Arno Therapeutics and has been a director of Arno Therapeutics ("Arno") since 2014. At Arno, his responsibilities included leading the clinical development and regulatory affairs teams to support the company's pipeline. Prior to joining Arno in 2007, Dr. Zukiwski served as chief medical officer and executive vice president of clinical research at MedImmune LLC ("MedImmune"). Prior to MedImmune, Dr. Zukiwski held several roles of increasing responsibility at Johnson & Johnson's ("J&J") medical affairs and clinical development functions at Johnson & Johnson Pharmaceutical Research & Development LLC ("J&JPRD"), Centocor R&D and Ortho Biotech. Before joining J&J, he served in clinical oncology positions at pharmaceutical companies such as Hoffmann-LaRoche, Glaxo Wellcome and Rhone-Poulenc Rorer. Dr. Zukiwski has more than 21 years of experience in global drug development and supported the clinical evaluation and registration of many successful oncology therapeutic agents, including Taxotere, Xeloda, Procrit/Eprex, Velcade, Yondelis, and Doxil. He previously served as a member of medical advisory board at Gem Pharmaceuticals, LLC and served as a director of Ambit Biosciences Corporation. Dr. Zukiwski holds a bachelor's degree in pharmacy from the Universityof Alberta and a Doctor of Medicine degree from the University of Calgary. He conducted his post-graduate training at St. Thomas Hospital Medical Center in Akron, Ohio and the University of Texas MD Anderson Cancer Center.
- 王春华
王春华自2017年起担任CASI的首席运营官。王女士负责公司后台运营和生产现场管理，主管人力资源、IT、通信、政务、法律、法规事务、研发等工作。在加入CASI之前，王女士于2015年至2017年担任Vcanbio的副总裁。在加入Vcanbio之前，王女士曾于2014年至2015年担任Marsh & McLennan公司的副总裁。2011年至2014年，王女士在Schneider Electric SA.担任人力资源总监。在加入Schneider Electric SA之前，王女士于2002年至2010年在Tycoman Co., Ltd.担任副总裁，在此之前，王女士是Tyco Healthcare的人力资源总监。在王女士职业生涯的早期，她曾在国有企业从事人力资源领域的工作。王女士在中国东北大学获得冶金学学士学位，在中国人民大学获得经济学硕士学位。
Chunhua Wang,has been chief operation officer of CASI since 2017. Ms. Wang is responsible for the Company's back-office operation and manufacturing site management and is account for human resources, IT, communication, government affairs, legal, regulatory affairs, R&D, etc. Prior to joining CASI, Ms. Wang was the vice president of Vcanbio from 2015 to 2017. Before she joined Vcanbio, Ms. Wang was the VP at Marsh & McLennan Companies from 2014 to 2015. From 2011 to 2014, Ms. Wang served as the HR director at Schneider Electric SA. Prior her experience in Schneider, Ms. Wang was the vice president at Tycoman Co., Ltd. a medical device company, from 2002 to 2010, and before that, Ms. Wang was the HR director at Tyco Healthcare. Earlier in Ms. Wang's career, she worked at state-owned enterprises in human resource field. Ms. Wang received the bachelor's degree in Metallurgy from China Northeastern University, and master's degree in economics from Renmin University of China.- 王春华自2017年起担任CASI的首席运营官。王女士负责公司后台运营和生产现场管理，主管人力资源、IT、通信、政务、法律、法规事务、研发等工作。在加入CASI之前，王女士于2015年至2017年担任Vcanbio的副总裁。在加入Vcanbio之前，王女士曾于2014年至2015年担任Marsh & McLennan公司的副总裁。2011年至2014年，王女士在Schneider Electric SA.担任人力资源总监。在加入Schneider Electric SA之前，王女士于2002年至2010年在Tycoman Co., Ltd.担任副总裁，在此之前，王女士是Tyco Healthcare的人力资源总监。在王女士职业生涯的早期，她曾在国有企业从事人力资源领域的工作。王女士在中国东北大学获得冶金学学士学位，在中国人民大学获得经济学硕士学位。
- Chunhua Wang,has been chief operation officer of CASI since 2017. Ms. Wang is responsible for the Company's back-office operation and manufacturing site management and is account for human resources, IT, communication, government affairs, legal, regulatory affairs, R&D, etc. Prior to joining CASI, Ms. Wang was the vice president of Vcanbio from 2015 to 2017. Before she joined Vcanbio, Ms. Wang was the VP at Marsh & McLennan Companies from 2014 to 2015. From 2011 to 2014, Ms. Wang served as the HR director at Schneider Electric SA. Prior her experience in Schneider, Ms. Wang was the vice president at Tycoman Co., Ltd. a medical device company, from 2002 to 2010, and before that, Ms. Wang was the HR director at Tyco Healthcare. Earlier in Ms. Wang's career, she worked at state-owned enterprises in human resource field. Ms. Wang received the bachelor's degree in Metallurgy from China Northeastern University, and master's degree in economics from Renmin University of China.
- 钱坤
钱坤，自2022年1月起担任CASI全球财务总监兼副总裁。她负责所有公司财务职能，包括公司财务总监、财务规划和分析、财务、税务和区域财务活动。在加入CASI之前，她于2021年至2022年在Guazi.com担任财务总监。在此之前，她曾于2016-2020年在Wanda Sports Group旗下产业集团万达体育集团担任全球财务总监，并于2019年在纳斯达克完成首次公开募股。2014年至2016年任职于Weichai Group国际金融部。在2014年之前，她是一名高级审计经理，在普华永道钟田律师事务所北京办事处和普华永道新加坡办事处工作了近10年。钱女士在对外经济贸易大学获得管理学学士学位。她是新罕布什尔州的注册会计师，也是美国注册会计师协会的会员。钱女士还具有中国注册会计师和加拿大特许专业会计师的资格。
Kun Qian,has been CASI's global controller and vice president since January 2022. She is responsible for all corporate finance functions, including corporate controller, financial planning and analysis, treasury, tax, and regional finance activities. Prior to joining CASI, she served as financial director in Guazi.com from 2021 to 2022. Prior to that, she served as global controller at Wanda Sports Group, an industry group of Wanda Group, from 2016-2020 and completed its initial public offering in Nasdaq in 2019. She worked in international finance department at Weichai Group from 2014 to 2016. Prior to 2014, she was a senior audit manager and spent nearly 10 years with PricewaterhouseCoopers Zhong Tian LLP, Beijing office and PricewaterhouseCoopers, Singapore office. Ms. Qian received a bachelor's degree in Management from University of International Business and Economics. She is a Certified Public Accountant in the State of New Hampshire and a member of American Institute of Certified Public Accountants. Ms. Qian also qualifies as a Certified Public Accountant in China and a Chartered Professional Accountant in Canada.- 钱坤，自2022年1月起担任CASI全球财务总监兼副总裁。她负责所有公司财务职能，包括公司财务总监、财务规划和分析、财务、税务和区域财务活动。在加入CASI之前，她于2021年至2022年在Guazi.com担任财务总监。在此之前，她曾于2016-2020年在Wanda Sports Group旗下产业集团万达体育集团担任全球财务总监，并于2019年在纳斯达克完成首次公开募股。2014年至2016年任职于Weichai Group国际金融部。在2014年之前，她是一名高级审计经理，在普华永道钟田律师事务所北京办事处和普华永道新加坡办事处工作了近10年。钱女士在对外经济贸易大学获得管理学学士学位。她是新罕布什尔州的注册会计师，也是美国注册会计师协会的会员。钱女士还具有中国注册会计师和加拿大特许专业会计师的资格。
- Kun Qian,has been CASI's global controller and vice president since January 2022. She is responsible for all corporate finance functions, including corporate controller, financial planning and analysis, treasury, tax, and regional finance activities. Prior to joining CASI, she served as financial director in Guazi.com from 2021 to 2022. Prior to that, she served as global controller at Wanda Sports Group, an industry group of Wanda Group, from 2016-2020 and completed its initial public offering in Nasdaq in 2019. She worked in international finance department at Weichai Group from 2014 to 2016. Prior to 2014, she was a senior audit manager and spent nearly 10 years with PricewaterhouseCoopers Zhong Tian LLP, Beijing office and PricewaterhouseCoopers, Singapore office. Ms. Qian received a bachelor's degree in Management from University of International Business and Economics. She is a Certified Public Accountant in the State of New Hampshire and a member of American Institute of Certified Public Accountants. Ms. Qian also qualifies as a Certified Public Accountant in China and a Chartered Professional Accountant in Canada.
- 高玮
高玮，自2023年1月起担任CASI的总法律顾问。在担任现职之前，Gao女士自2020年12月起担任法律总监。在加入CASI之前，高女士于2017年至2020年在Medtronic Beijing担任法务经理。此前，高女士曾于2012年至2017年担任Syngenta Beijing的法律顾问。2006年至2007年和2010年至2012年，高女士在Caterpillar担任法律顾问和高级顾问。在她职业生涯的早期，高女士曾于2008年至2010年在Commerce & Finance律师事务所担任诉讼律师，专门处理国际商业纠纷。2005年至2006年，高女士在Guo & Partners Attorneys At Law担任法律助理，开始了她的法律生涯。高女士在吉林大学获得经济法学士学位，在曼彻斯特大学获得国际商法法学硕士学位。
Wei Gao,has been serving as CASI's general counsel since January 2023. Prior to her current position, Ms. Gao was legal director since December 2020. Prior to joining CASI, Ms. Gao served as legal manager in Medtronic Beijing from 2017 to 2020. Earlier, Ms. Gao was a legal counsel of Syngenta Beijing from 2012 to 2017. From 2006 to 2007, and from 2010 to 2012, Ms. Gao served as legal consultant and senior consultant in Caterpillar. Earlier in her career, Ms. Gao worked as a litigation lawyer specializing international business dispute resolution in Commerce & Finance Law Offices from 2008 to 2010. Ms. Gao started her legal career as a legal assistant in Guo & Partners Attorneys At Law from 2005 to 2006. Ms. Gao received her bachelor's degree in Economic Law from Jilin University and LL.M. degree in International Business Law from the University of Manchester.- 高玮，自2023年1月起担任CASI的总法律顾问。在担任现职之前，Gao女士自2020年12月起担任法律总监。在加入CASI之前，高女士于2017年至2020年在Medtronic Beijing担任法务经理。此前，高女士曾于2012年至2017年担任Syngenta Beijing的法律顾问。2006年至2007年和2010年至2012年，高女士在Caterpillar担任法律顾问和高级顾问。在她职业生涯的早期，高女士曾于2008年至2010年在Commerce & Finance律师事务所担任诉讼律师，专门处理国际商业纠纷。2005年至2006年，高女士在Guo & Partners Attorneys At Law担任法律助理，开始了她的法律生涯。高女士在吉林大学获得经济法学士学位，在曼彻斯特大学获得国际商法法学硕士学位。
- Wei Gao,has been serving as CASI's general counsel since January 2023. Prior to her current position, Ms. Gao was legal director since December 2020. Prior to joining CASI, Ms. Gao served as legal manager in Medtronic Beijing from 2017 to 2020. Earlier, Ms. Gao was a legal counsel of Syngenta Beijing from 2012 to 2017. From 2006 to 2007, and from 2010 to 2012, Ms. Gao served as legal consultant and senior consultant in Caterpillar. Earlier in her career, Ms. Gao worked as a litigation lawyer specializing international business dispute resolution in Commerce & Finance Law Offices from 2008 to 2010. Ms. Gao started her legal career as a legal assistant in Guo & Partners Attorneys At Law from 2005 to 2006. Ms. Gao received her bachelor's degree in Economic Law from Jilin University and LL.M. degree in International Business Law from the University of Manchester.
- Huang Hai
Huang Hai，自2024年1月起担任CASI全球首席商务官（执行副总裁）。黄先生领导CASI全球商业化战略的制定，监督全球业务体系的建立，并管理市场扩张和战略业务合作伙伴关系。在加入CASI制药公司之前，黄先生曾担任复星凯特生物技术股份有限公司的首席执行官。黄先生于2016年至2020年在辉瑞中国工作，担任基本业务总经理、首席营销官/副总裁，然后是基本业务首席运营官。2013年至2016年，黄先生曾任职于美敦力，担任糖尿病BU大中华区总经理。从2011年到2013年，黄先生作为糖尿病BU的全国销售领导者与赛诺菲安万特合作。黄先生于1997年加入辉瑞，并担任销售总监至2010年。黄先生目前还担任上海CGT专委会执行主任和上海产学研专家组委员会成员。黄先生获得北京大学双MBA学位和兰州大学生物化学本科学位。
Huang Hai,has been global chief commercial officer (executive vice president) of CASI since January 2024. Mr. Huang leads the development of CASI's global commercialization strategy, overseeing the establishment of a global business system, and managing market expansion and strategic business partnerships. Prior to joining Casi Pharmaceuticals, Inc. , Mr. Huang served as the chief executive officer of Fosun Kite Biotechnology Co., Ltd. Mr. Huang worked with Pfizer China from 2016 to 2020, acting as general manager of essential business, chief marketing officer/vice president and then chief operating officer of essential business. From 2013 to 2016, Mr. Huang worked with Medtronic as a general manager of Diabetes BU for greater China region. From 2011 to 2013, Mr. Huang worked with Sanofi Aventis as a national sales leader of Diabetes BU. Mr. Huang joined Pfizer in 1997 and worked as sales director till 2010. Mr. Huang currently also holds positions as the Executive Director of the Shanghai CGT Special Committee and a member of the Shanghai Industry-Academia-Research Expert Group Committee. Mr. Huang received the Bi-MBA from Peking University and an undergraduate degree in Biochemistry from Lanzhou University.- Huang Hai，自2024年1月起担任CASI全球首席商务官（执行副总裁）。黄先生领导CASI全球商业化战略的制定，监督全球业务体系的建立，并管理市场扩张和战略业务合作伙伴关系。在加入CASI制药公司之前，黄先生曾担任复星凯特生物技术股份有限公司的首席执行官。黄先生于2016年至2020年在辉瑞中国工作，担任基本业务总经理、首席营销官/副总裁，然后是基本业务首席运营官。2013年至2016年，黄先生曾任职于美敦力，担任糖尿病BU大中华区总经理。从2011年到2013年，黄先生作为糖尿病BU的全国销售领导者与赛诺菲安万特合作。黄先生于1997年加入辉瑞，并担任销售总监至2010年。黄先生目前还担任上海CGT专委会执行主任和上海产学研专家组委员会成员。黄先生获得北京大学双MBA学位和兰州大学生物化学本科学位。
- Huang Hai,has been global chief commercial officer (executive vice president) of CASI since January 2024. Mr. Huang leads the development of CASI's global commercialization strategy, overseeing the establishment of a global business system, and managing market expansion and strategic business partnerships. Prior to joining Casi Pharmaceuticals, Inc. , Mr. Huang served as the chief executive officer of Fosun Kite Biotechnology Co., Ltd. Mr. Huang worked with Pfizer China from 2016 to 2020, acting as general manager of essential business, chief marketing officer/vice president and then chief operating officer of essential business. From 2013 to 2016, Mr. Huang worked with Medtronic as a general manager of Diabetes BU for greater China region. From 2011 to 2013, Mr. Huang worked with Sanofi Aventis as a national sales leader of Diabetes BU. Mr. Huang joined Pfizer in 1997 and worked as sales director till 2010. Mr. Huang currently also holds positions as the Executive Director of the Shanghai CGT Special Committee and a member of the Shanghai Industry-Academia-Research Expert Group Committee. Mr. Huang received the Bi-MBA from Peking University and an undergraduate degree in Biochemistry from Lanzhou University.